Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 8/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.40 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19652216 | 0.86 | FFAR1 (0.43) | NPY5RFFAR1MGLLTMEM97SIGMAR1 | |
| SCHEMBL19658406 | 0.84 | MCHR1 (0.46) | NPY5RMCHR1L3MBTL1 | |
| SCHEMBL19658391 | 0.83 | NPY5R (0.60) | NPY5RSETD2 | |
| SCHEMBL14321771 | 0.82 | NPY5R (0.61) | NPY5RPIK3CDSETD2MCHR1L3MBTL1 | |
| SCHEMBL19658738 | 0.81 | NPY5R (0.56) | NPY5RMCHR1MBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL19658386 | 0.80 | NOTUM (0.58) | SIGMAR1L3MBTL1 | |
| SCHEMBL19658404 | 0.80 | NOTUM (0.58) | NPY5RPIK3CDSETD2MCHR1 | |
| SCHEMBL6501087 | 0.79 | NOTUM (0.57) | FFAR1MGLLL3MBTL1 | |
| SCHEMBL18617819 | 0.78 | L3MBTL3 (0.47) | FFAR1MGLLALOX5MBTD1TP53BP1 | |
| SCHEMBL22919216 | 0.77 | SYK (0.46) | NPY5RPIK3CDMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023168291-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | PIK3R3, JAK2, JAK3 | NPY5R 500/4885FFAR1 1906/4885PIK3CD 14/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | NPY5R 1431/4885FFAR1 2401/4885PIK3CD 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.